Propofol inhibits in vitro platelet aggregation in human whole blood.
To help clarify the mechanism of propofol-induced vasodilation, we investigated whether propofol, at concentrations ranging from 10(-6) to 10(-3) M, inhibited platelet aggregation in human whole blood. Propofol inhibited platelet aggregation induced by adenosine diphosphate, collagen, or arachidonic acid in a concentration-dependent manner, with a 50% inhibited concentration (micromol/L) of 136 +/- 9.8 for adenosine diphosphate, 77.8 +/- 6.6 for collagen, and 71.8 +/- 5.4 for arachidonic acid. In platelet-rich plasma, propofol had no significant antiaggregant effect except when arachidonic acid was used as the aggregant (50% inhibited concentration 105 +/- 9.9 micromol/L). The antiaggregant effect of propofol in platelet-rich plasma was increased in the presence of red blood cells or leukocytes in a cell number-dependent manner. We conclude that propofol reduces the platelet activity in human whole blood in vitro.
De La Cruz
J P
JP
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
Carmona
J A
JA
Paez
M V
MV
Blanco
E
E
Sanchez De La Cuesta
F
F
D000328:Adult; D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D015742:Propofol / Q000494:pharmacology*
D018686:Anesthetics, Intravenous; D010975:Platelet Aggregation Inhibitors; D015742:Propofol